Wednesday, December 19, 2018

3375. Miniature Schnauzer skin disease: Control of Atopic Dermatitis using Apoquel (oclacitinib tablet)

Dec 18, 2018

Today, a dog owner was very satisfied with the disappearance of pruritus and skin flakes in her Miniature Schnauzer that had atopic dermatitis for the past 4 years.
"His medical bills cost more than mine," the woman in her 40s did church work in Myanmar, helping out with the drug addict problems.
"Look at the positive side," I replied. "You are healthy. Do you want to incur higher medical bills than your dog!"

The dog was on apoquel 3.6 mg 2x/day for the last 14 days. The vet did not give maintenance dose of 1 tablet 1x/day. He was on antibiotics, ninazol and a pred inj in the first 14 days.

Food allergy tests showed the dog was allergic to duck, turkey, pork and fish. So the owner now feeds chicken, rice, carrots and brocolli. The amount of stool is less compared to the dry dog food.

Apoquel is a synthetic Janus Kinese (JAK) inhibitor.
Dosage is 0.4 to 0.6 mg/kg, oral, twice daily up to 14 days and once daily for maintenance therapy, with or without food. Not for breeding, pregnant or lactating dogs or dogs less than 12 months of age.
Dogs should be monitored for the development of infections, including demodicosis and neoplasia. It is not a corticosteroid or an antihistamine. Its use has not been evaluated with the use of glucocorticoids, cyclosporine or other systemic immunosuppressive agents.

Apoquel trials by the company found the drug effective.
Effectiveness for the Control of Atopic Dermatitis
1. Treatment success for pruritus up to Day 28
2. Treatment for success for skin lesions up to Day 28.

Effectiveness for the Control of Pruritus with Allergic Dermatitis

History of allergic dermatitis is attributed to one or more of the following conditions:
atopic dermatitis, flea allergy, food allergy, contact allergy and other/unspecified allergic dermatitis.

1. Treatment success for pruritus up to Day 7
2. Treatment for success for skin lesions up to Day 7.

No comments:

Post a Comment